{"nctId":"NCT01377467","briefTitle":"Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients","startDateStruct":{"date":"2011-06"},"conditions":["Osteoporosis","Chronic Kidney Disease"],"count":90,"armGroups":[{"label":"Denosumab","type":"EXPERIMENTAL","interventionNames":["Drug: Denosumab (Prolia)"]},{"label":"Control","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Denosumab (Prolia)","otherNames":["Prolia"]}],"eligibilityModule":{"eligibilityCriteria":"The key inclusion criteria are:\n\n1. Male or female adult de novo kidney, kidney-pancreas or kidney-islet, or kidney-liver transplant recipients\n2. Functioning graft within 28 days after transplantation (creatinine having decreased to \\<200 micromol/l without the need for dialysis)\n3. Being on standard triple immunosuppression including a calcineurin antagonist (cyclosporine or tacrolimus), mycophenolate (MMF or MPA) and steroids, with or without induction treatment with basiliximab or anti-thymocyte globulin\n\nKey exclusion criteria are:\n\n1. Age \\<18 years\n2. Rising creatinine after initial drop \\<200 micromol/l or creatinine \\>200 micromol/l at baseline\n3. Evidence of early acute rejection, either suspected clinically and/or proven by biopsy\n4. Presence of severe osteoporosis as evidenced by a T score \\<-4 at the hip, femoral neck or any of the 4 vertebrae L1 to L4\n5. Evidence of severe hyper- or hypoparathyroidism (iPTH \\>800 ng/l or \\<10 ng/l)\n6. Hypocalcemia (total calcium \\<1.8 mmol/l) or hypercalcemia (total calcium \\>2.7 mmol/l)\n7. Steroid-free de novo immunosuppression scheme","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 12","description":"The total lumbar spine BMD was measured via Dual Energy X-ray Absorptiometry (DXA) and was expressed in g/cm2 hydroxylapatite","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"3.8"},{"groupId":"OG001","value":"-0.3","spread":"5.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change in BMD at the Total Hip From Baseline to Month 12","description":"The total hip BMD was measured via Dual Energy X-ray Absorptiometry (DXA) and was expressed in g/cm2 hydroxylapatite","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"3.7"},{"groupId":"OG001","value":"0.5","spread":"4.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change in BMD at the Femoral Neck From Baseline to Month 12","description":"The total femoral neck BMD was measured via Dual Energy X-ray Absorptiometry (DXA) and was expressed in g/cm2 hydroxylapatite","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"4.7"},{"groupId":"OG001","value":"0.8","spread":"6.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 6","description":"The total lumbar spine BMD was measured via DXA and was expressed in g/cm2 hydroxylapatite.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"3.3"},{"groupId":"OG001","value":"-1.5","spread":"4.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change in BMD at the Total Hip From Baseline to Month 6","description":"The total hip BMD was measured via DXA and was expressed in g/cm2 hydroxylapatite","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"2.4"},{"groupId":"OG001","value":"-0.3","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change in BMD at the Femoral Neck From Baseline to Month 6","description":"The femoral neck BMD was measured via DXA and was expressed in g/cm2 hydroxylapatite","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"4.0"},{"groupId":"OG001","value":"-0.8","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"Beta-CTX at Baseline and Months 3, 6 and 12","description":"Blood concentrations of beta-CTX (microgram/L)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.635","spread":null},{"groupId":"OG001","value":"0.772","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.129","spread":null},{"groupId":"OG001","value":"0.590","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.204","spread":null},{"groupId":"OG001","value":"0.612","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.389","spread":null},{"groupId":"OG001","value":"0.794","spread":null}]}]}]},{"type":"SECONDARY","title":"P1NP at Baseline and Months 3, 6 and 12","description":"Blood concentrations of P1NP were measured in microgram/L","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.222","spread":null},{"groupId":"OG001","value":"77.808","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.976","spread":null},{"groupId":"OG001","value":"108.699","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.347","spread":null},{"groupId":"OG001","value":"107.072","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.953","spread":null},{"groupId":"OG001","value":"132.439","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Blood Levels of Calcium (mmol/L) at Baseline and Months 0.5, 1, 2, 3, 6, 12","description":"Blood levels of calcium (mmol/L) were measured at baseline and at months 0.5, 1, 2, 3, 6, and 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.320","spread":null},{"groupId":"OG001","value":"2.317","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.131","spread":null},{"groupId":"OG001","value":"2.405","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.293","spread":null},{"groupId":"OG001","value":"2.444","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.420","spread":null},{"groupId":"OG001","value":"2.480","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.404","spread":null},{"groupId":"OG001","value":"2.461","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.463","spread":null},{"groupId":"OG001","value":"2.453","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.480","spread":null},{"groupId":"OG001","value":"2.509","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Blood Levels of Phosphate (mmol/L) at Baseline and Months 0.5, 1, 2, 3, 6, 12","description":"Blood levels of phosphate (mmol/L) were measured at baseline and at months 0.5, 1, 2, 3, 6, 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.582","spread":null},{"groupId":"OG001","value":"0.586","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.525","spread":null},{"groupId":"OG001","value":"0.714","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.605","spread":null},{"groupId":"OG001","value":"0.726","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.726","spread":null},{"groupId":"OG001","value":"0.812","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.742","spread":null},{"groupId":"OG001","value":"0.776","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.804","spread":null},{"groupId":"OG001","value":"0.849","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.842","spread":null},{"groupId":"OG001","value":"0.902","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Blood Levels of PTH (ng/L) at Baseline and Months 3, 6, and 12","description":"Blood levels of PTH (ng/L) were measured at baseline and at months 3, 6, and 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163.110","spread":null},{"groupId":"OG001","value":"147.300","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"173.573","spread":null},{"groupId":"OG001","value":"111.563","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157.043","spread":null},{"groupId":"OG001","value":"99.420","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106.650","spread":null},{"groupId":"OG001","value":"100.705","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"25-OH-vitamin D3","description":"Blood levels of 25-OH-vitamin D3 were measured as microgramm/L","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.378","spread":null},{"groupId":"OG001","value":"18.058","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.632","spread":null},{"groupId":"OG001","value":"22.903","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.395","spread":null},{"groupId":"OG001","value":"26.728","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.546","spread":null},{"groupId":"OG001","value":"28.358","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"1,25-(OH)2 Vitamin D3","description":"Blood levels of 1,25-(OH)2 vitamin D3 were measured as ng/L","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.556","spread":null},{"groupId":"OG001","value":"34.171","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.533","spread":null},{"groupId":"OG001","value":"55.276","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.175","spread":null},{"groupId":"OG001","value":"58.074","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.208","spread":null},{"groupId":"OG001","value":"51.494","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Total Volumetric Bone Mineral Densitiy (Tot.vBMD) at the Distal Tibia","description":"Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mg HA/cm3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"-0.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Cortical Volumetric Bone Mineral Densitiy (Ct.vBMD) at the Distal Tibia","description":"Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mg HA/cm3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null},{"groupId":"OG001","value":"-0.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Trabecular Volumetric Bone Mineral Densitiy (Tb.vBMD) at the Distal Tibia","description":"Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mg HA/cm3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Cortical Thickness (Ct.Th) at the Distal Tibia","description":"Cortical thickness was measured via HR-pQCT (Xtreme CT) at the distal tibia and was expressed as mm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"-0.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Total Volumetric Bone Mineral Densitiy (Tot.vBMD) at the Distal Radius","description":"Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mg HA/cm3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"-1.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Cortical Volumetric Bone Mineral Densitiy (Ct.vBMD) at the Distal Radius","description":"Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mg HA/cm3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":null},{"groupId":"OG001","value":"-0.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Trabecular Volumetric Bone Mineral Densitiy (Tb.vBMD) at the Distal Radius","description":"Volumetric BMD (vBMD) was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mg HA/cm3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Cortical Thickness (Ct.Th) at the Distal Radius","description":"Cortical thickness was measured via HR-pQCT (Xtreme CT) at the distal radius and was expressed as mm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"-3.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":31,"n":46},"commonTop":["Urinary tract infections","Hypocalcemia","Exanthema","Sore throat","Tremor"]}}}